Paul Berns

Mr. Berns joined ARCH in 2018 as a Venture Partner and moved into a Managing Director role in 2021. He is Chairman of the board of directors of Neumora Therapeutics, Happy AI, Epirium Bio, and HI Bio. Additionally, Mr. Berns is a board member of Unity Biotechnology (UBX) and EQRx. Mr. Berns previously served on the boards of Jazz Pharmaceuticals, PLC, MC2 Therapeutics, Menlo Therapeutics, Anacor Pharmaceuticals, XenoPort, Allos Therapeutics, and Bone Care International. Mr. Berns is also the Chief Executive Officer of Neumora Therapeutics, and served as President, Chief Executive Officer and Chairman of the board of directors at Anacor Pharmaceuticals from 2014 until its acquisition by Pfizer, Inc. in 2016. Mr. Berns served as President and Chief Executive Officer of Allos Therapeutics, Inc., a biotechnology company, from 2006 to 2012 when it was acquired by Spectrum Pharmaceuticals and was the President and Chief Executive Officer of Bone Care International, Inc., a specialty pharmaceutical company, from 2002 to 2005 when it was acquired by Genzyme Corporation. Mr. Berns was a consultant to the pharmaceutical industry from July 2016 to August 2018, as well as from August 2012 to March 2014 and from July 2005 to March 2006. Prior to that, Mr. Berns was Vice President and General Manager of the Immunology, Oncology and Pain Therapeutics business unit of Abbott Laboratories from 2001 to 2002, and from 2000 to 2001, he served as Vice President, Marketing of BASF Pharmaceuticals/Knoll, when it was acquired by Abbott Laboratories in 2001. Earlier in his career, Mr. Berns held various positions, including senior management roles, at Bristol Myers Squibb (BMS) from 1990 to 2000. Mr. Berns received his B.S. in Economics from the University of Wisconsin.